Studies a light device for dry age-related macular degeneration in routine care
Collects real-life data on light treatment for dry macular degeneration in routine clinics.
Plain-language title generated from the registry record
Registry title: A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (GLOBALIGHT)
Key facts
- Where
- Beverly Hills, Charleston, Cincinnati, McAllen, and Silverdale, United StatesSee the 5 sites
Where in United States
- Retina-Vitreous Associates Medical GroupBeverly Hills, United StatesNot yet recruiting
- Carolina Eyecare PhysiciansCharleston, United StatesNot yet recruiting
- Cincinnati Eye InstituteCincinnati, United StatesNot yet recruiting
- Valley Retina InstituteMcAllen, United StatesTaking people
- Pacific Northwest RetinaSilverdale, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- LumiThera, Inc.
- Trial code
- NCT06351605
- Record updated
- 22 September 2026
- Original description
The purpose of this registry study is to collect real life data pertaining to the safety and clinical effectiveness of multi-wavelength photobiomodulation (PBM) as provided by the Valeda Light Delivery System in participants with dry age-related macular degeneration (AMD) in routine clinical practice. Data will be collected retrospectively and prospectively.Read full original descriptionShow less
A Multi-Center Registry Study to Assess the Safety and Effectiveness of Photobiomodulation (PBM) in Participants With Dry Age-Related Macular Degeneration (AMD) (GLOBALIGHT)
The purpose of this registry study is to collect real life data pertaining to the safety and clinical effectiveness of multi-wavelength photobiomodulation (PBM) as provided by the Valeda Light Delivery System in participants with dry age-related macular degeneration (AMD) in routine clinical practice. Data will be collected retrospectively and prospectively.
PBM involves the use of visible light to near infrared light (NIR) (500-1000 nanometers) produced by a laser or a non-coherent light source applied to the surface of the body to activate mitochondrial respiratory chain components, stabilize metabolic function, and promote cellular proliferation.
This registry study will be conducted in Europe, the US, and select other countries approved by their regulatory agency.
This registry study was initiated as a combined retrospective and prospective data collection effort. After the acquisition of LumiThera by Alcon Research, LLC in September 2025, the study was amended to prospectively collect data from U.S. sites starting in July 2026.
Inclusion: Diagnosis or confirmation of diagnosis of dry AMD disease by Investigator; Able to communicate well with the Investigator and able to understand and comply with the requirements of the study; Informed of the nature of this study and has provided written, informed consent; (participants enrolled retrospectively will need to be contacted and sign an informed consent form prior to their data being used).
Exclusion: Use of any photosensitizing agent (e.g. topicals, injectables) activated by the Valeda Light Deliver System within 30 days prior to treatment without consulting participant's physician; Known photosensitivity to yellow light, red light, or near infrared radiation (NIR), or has a history of light activated central nervous system disorders (e.g. epilepsy, migraine); In the opinion of the Investigator, is unlikely to comply with the study protocol or has a history or current evidence of any condition that, in the opinion of the investigator, might interfere with the participant's involvement in the trial, or is not in the best interest of the participant; US Sites Only: Center-involving geographic atrophy; Neovascular maculopathy.